Overview
Q2 2022
Quarterly Results
Jun 30, 2022
Price
Change
MKT Cap
Volume
Corbus is committed to leveraging our expertise in immunology to fulfill our purpose of developing innovative new medicines that improve the lives of people living with inflammatory, fibrotic, and metabolic diseases, and cancer. Corbus’ current pipeline includes small molecules that activate or inhibit the endocannabinoid system and anti-integrin monoclonal antibodies that block activation of TGFβ. Corbus is headquartered in Norwood, Massachusetts.
Sign up for email alerts
Be the first to receive breaking news
Sign up today
Yuval Cohen, Ph.D.
Chief Executive Officer, Director
Yuval Cohen, Ph.D., joined Corbus as co-founder and Chief Executive Officer in 2014. Prior to joining Corbus, he was the President and co-founder of Celsus Therapeutics (Nasdaq: CLTX) from 2005 to June 2013. Dr. Cohen has a Ph.D., summa
View Full Bio
Rachael Brake, Ph.D.
Chief Scientific Officer
Rachael Brake, Ph.D., has successfully developed innovative drug discovery and clinical development oncology programs centered around patient-focused, unmet medical needs. Prior to joining Corbus in 2021, Dr. Brake most recently served at
View Full Bio
Craig Millian, MBA
Chief Operating Officer
Craig Millian serves as Corbus’ Chief Operating Officer. Mr. Millian has successfully led commercial organizations at several biopharmaceutical companies and helped build leading brands at all stages of product development and
View Full Bio
Sean Moran, CPA, MBA
Chief Financial Officer
Sean Moran, CPA, joined Corbus in January 2014. He has more than twenty years of senior financial experience with emerging biotechnology, drug delivery, and medical device companies. Mr. Moran has successfully managed operations from start
View Full Bio
Christina Bertsch
Head of Human Resources
Christina Bertsch joined Corbus in April 2020. She is an accomplished senior human resource executive providing strategic HR consulting services to both large and small businesses across a variety of industries. Her expertise spans the
View Full Bio
Alan Holmer
Chairman of the Board
Alan F. Holmer served from 1996 to 2005 as President and Chief Executive Officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), an organization that represents the worldwide interests of leading pharmaceutical and
View Full Bio
Avery W. Catlin previously served as Senior Vice President, Chief Financial Officer, and Secretary of Celldex Therapeutics, Inc., a public biopharmaceutical company. Prior to joining Celldex Therapeutics, Inc. in January 2000, he served as
View Full Bio
Yuval Cohen, Ph.D.
Chief Executive Officer, Director
Yuval Cohen, Ph.D., joined Corbus as co-founder and Chief Executive Officer in 2014. Prior to joining Corbus, he was the President and co-founder of Celsus Therapeutics (Nasdaq: CLTX) from 2005 to June 2013. Dr. Cohen has a Ph.D., summa
View Full Bio
Rachelle Jacques
Director
Ms. Jacques is the President and Chief Executive Officer of Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari”), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory
View Full Bio
John Jenkins, M.D.
Director
Dr. Jenkins served as the Director of the Office of New Drugs (OND) at U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) from 2002 to 2017, where he was responsible for more than 1,000 agency
View Full Bio
Pete Salzmann, M.D., MBA
Director
Dr. Salzmann has served as the Chief Executive Officer of Immunovant, Inc. (NASDAQ: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, since June 2019, and as a member
View Full Bio
Anne Altmeyer, Ph.D.
Director
Dr. Altmeyer is currently the President and CEO of TigaTx, Inc. She previously served as the Chief Business Officer of Sigilon Therapeutics and Adicet Bio. Dr. Altmeyer also held roles of increasing responsibility in corporate development
View Full Bio
